TJC Proposes More Rigid Standards for Imaging
The Joint Commission (TJC) is seeking comment on it’s proposed new standards for imaging which are much more restrictive on diagnostic imaging practices.
The Joint Commission (TJC) is seeking comment on it’s proposed new standards for imaging which are much more restrictive on diagnostic imaging practices.
BloXR’s “Ultra Blox X-ray Attenuating Cream” uses a ceramic powder that contains Bismuth Oxide to reduce hand exposures 50 – 85%. The product is to be released 09/09/13. 08/15/13
Those involved with T&R officials and whole blood irradiators need to note that there has been a change in address for submitting fingerprints to the NRC.
Radium-223 injectable prostate cancer therapy has gained FDA approval as “Xofigo” Bayer Pharmaceutical announced. 05/16/13
Spectrum Dynamics, makers of the D-SPECT camera system has been sold to Biosensors International Group of Singapore.
The NRC will open a social media outlet called “NRC Chat” on April 30, 2013 as a twice monthly single topic open forum with an NRC expert.
As of 3/7/13 the NRC has issued a revised approved “Board Certification” listing for medical uses. It notes a limit of acceptance of only four(4) years from the date of issue only for new American Board of Radiology Certified physicians and physicists. It was previously seven(7) years. 03/19/13
The SNMMI has introduced a resource center for radiation dose optimization in Nuclear Medicine.
The SNMMI will release on 2/21/13 a pamphlet noting “Five Things Physicians and Patients Should Question”. These are targeted, evidence-based recommendations to assist in the proper selection of imaging procedures. 2/18.13
The NRC has finalized that Ra-223 “Alpharadin” will be ruled a 35.300 radiopharmaceutical and for those institutions already licensed under this section with AU granted full 35.300 status – No Amendment needed.